Despite advances in conventional treatment modalities, patients with metastatic CRC often face limited options and poor outcomes. Chimeric antigen receptor-T (CAR-T) cell therapy, initially successful ...

Carisma Therapeutics is developing a unique, differentiated immuno-oncology (IO) treatment for solid tumors based on chimeric antigen receptor macrophages (CAR-M). Current IO treatments have ...

have developed a way to add features to T cells to help them overcome mechanisms of chimeric antigen receptor (CAR) T cell therapy resistance. Their new system is outlined in a paper published ...